title: What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?
authors.affiliation: Division of Hematological Malignancies, H. Lee Moffitt Cancer Center and Research Institute, and the University of South Florida , Tampa, FL , USA.
authors.forename: Samir
authors.initials: S
authors.lastname: Dalia
authors.forename: Samantha
authors.initials: S
authors.lastname: Price
authors.forename: Peter
authors.initials: P
authors.lastname: Forsyth
authors.forename: Lubomir
authors.initials: L
authors.lastname: Sokol
authors.forename: Michael
authors.initials: M
authors.lastname: Jaglal
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate